Purpose Invasive fungal infection (IFI) causes disability/death in patients with hematologic
malignancy (HM) receiving chemotherapy or hematopoietic stem cell transplant (HSCT) …

Invasive fungal infection (IFI) causes morbidity and mortality among patients with
hematological malignancies who receive cytotoxic chemotherapy or hematopoietic stem cell …

Background The use of newer azoles as prophylaxis in hematological patients undergoing
stem cell transplantation or immunosuppressive chemotherapy has been shown to decrease …

Invasive fungal disease (IFD) is a major infectious complication in patients with
hematological malignancies. In this study, we examined 4889 courses of chemotherapy in …

Invasive fungal infections (IFIs) are a leading cause of morbidity and attributable mortality in
oncohematologic patients. Timely diagnosis is essential but challenging. Herein we …

Abstract The China Assessment of Antifungal Therapy in Hematological Disease study, the
first large-scale observational study of invasive fungal disease (IFD) in China, enrolled 1401 …

Patients with hematologic malignancies and hematopoietic cell transplant recipients (HCT)
are at high risk for invasive fungal disease (IFD). The practice of antifungal prophylaxis with …

Invasive fungal infections (IFI) remain a leading cause of morbidity and mortality in
immunocompromised patients. This retrospective single-center study analyzed incidence …

Background. With use of data from the Prospective Antifungal Therapy (PATH) Alliance
registry, we performed this multicenter, prospective, observational study to assess the …

This stud y examined the epidemiology, risk factors, management, and outcome of invasive
fungal infection (IFI) in patients receiving chemotherapy for hematological malignancy in …